Cugene Presents Preclinical Data on TILKine-2 at the Society for Immunotherapy of Cancer (SITC 2021) Annual Meeting

Cugene unveils preclinical data on TILKine-2, showcasing its robust anti-tumor efficacy through TIL-targeting, cis-activation and expansion at the tumor site. This approach reduces systemic toxicity and enhances the therapeutic window, positioning TILKine-2 as a strong therapeutic agent for further clinical development.